<DOC>
	<DOCNO>NCT00363129</DOCNO>
	<brief_summary>RATIONALE : Vitamin E may prevent peripheral neuropathy cause chemotherapy patient cancer . It yet know whether vitamin E effective placebo prevent peripheral neuropathy cause chemotherapy patient receive chemotherapy cancer . PURPOSE : This randomized phase III trial study vitamin E see well work compare placebo prevent peripheral neuropathy cause chemotherapy patient receive chemotherapy cancer .</brief_summary>
	<brief_title>Vitamin E Preventing Peripheral Neuropathy Caused Chemotherapy Patients Receiving Chemotherapy Cancer</brief_title>
	<detailed_description>OUTLINE : This randomize , double-blind , placebo-controlled , multicenter study . Patients stratify accord type chemotherapy ( taxane v cisplatin v carboplatin v oxaliplatin vs combination ) , age ( ≤ 50 year vs &gt; 50 year ) , gender . Patients randomize 1 2 treatment arm . OBJECTIVES : Primary - Compare incidence chemotherapy-induced sensory peripheral neuropathy ≥ grade 2 patient undergoing curative neurotoxic chemotherapy cancer treat vitamin E v placebo . Secondary - Compare proportion patient require dose reduction chemotherapy secondary sensory peripheral neuropathy . - Compare proportion patient stop chemotherapy treatment complete secondary sensory peripheral neuropathy . - Assess toxicity vitamin E patient . After completion study treatment , patient follow 6 month .</detailed_description>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Neurotoxicity Syndromes</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin E</mesh_term>
	<mesh_term>Tocopherols</mesh_term>
	<mesh_term>Tocotrienols</mesh_term>
	<mesh_term>alpha-Tocopherol</mesh_term>
	<criteria>Required Characteristics : 1 . Scheduled undergo curativeintent adjuvant treatment neurotoxic chemotherapy . Patients must his/her tumor remove , may microscopic residual disease , residual margin involvement still eligible . The patient 's chemotherapy regimen must include one follow neurotoxic chemotherapeutic agent : taxanes ( paclitaxel , docetaxel ) ; platinum compound ( cisplatin , carboplatin , oxaliplatin ) ( oxaliplatin patient preferentially enrol protocol N04C7 available ) . 2 . ≥ 18 year age 3 . Ability sign inform consent understand nature placebocontrolled trial 4 . ECOG Performance Status ( PS ) 0 , 1 , 2 e.g . 5 . Ability complete questionnaire ( ) assistance 6 . Life expectancy ≥ 6 month Contraindications : 1 . Undergoing chemotherapy palliative care 2 . Preexisting history peripheral neuropathy due cause ( diabetes , alcohol , toxin , hereditary , etc ) . 3 . Prior treatment neurotoxic chemotherapy ( exception : Patient start neurotoxic chemotherapy ≤ 4 day start vitamin E study treat previously neurotoxic chemotherapy agent ) . 4 . Taking regular opioidcontaining medication . ( Exception : opioids , give short term treatment chemotherapyinduced myalgias arthralgia cause taxanes permit . ) 5 . Concurrent treatment anticonvulsant , tricyclic antidepressant , neuropathic pain medication agent carbamazepine , phenytoin , valproic acid , gabapentin , lamotrigine , topical lidocaine patch , capsaicin cream , etc . 6 . History coronary artery disease ( i.e . MI , PTCA , CABG ≤ 5 year diagnosis congestive heart failure NY heart class IIV ) Valve replacement permit long patient fully recover surgery . 7 . Other medical condition , opinion treat physician/allied health professional would make protocol unreasonably hazardous patient . 8 . Vitamin E supplementation reason ≤ 7 day prior randomization . ( Exception : one multivitamin per day contain ≤ 100 IU [ mg ] Vitamin E , permit . ) 9 . Any following : pregnant woman , nurse woman men woman childbearing potential unwilling employ adequate contraception 10 . Taking anticoagulant medication ( i.e . coumadin , low molecular weight heparin ( LMWH ) , platelet aggregation inhibitor clopidgrel aspirin ) exception 1 mg/day coumadin central line maintenance allow . 11 . Diagnosed diabetes require insulin oral hypoglycemic medication 12 . Head neck cancer 13 . Scheduled undergo radiation therapy study 14 . History hemorrhagic stroke 15 . Patients receive neoadjuvant therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>neurotoxicity</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>